Research Article
Synthesis, Characterization, and Anticancer Activity of New Quinazoline Derivatives against MCF-7 Cells
Table 2
The IC50 concentration of the quinazolinone-based compounds against MCF-7, MCF-10, and WRL-68 cell lines after 24, 48, and 72 h.
| | Compound | Cell line | Classification | IC50 (g/mL) | | 24 h | 48 h | 72 h |
| | (1) | MCF-7 | Breast cancer cells | 8.063 10−6 mol/L | 7.599 10−6 mol/L | 6.246 10−6 mol/L | | MCF-10 | Normal breast cells | 0.483 10−6 mol/L | 0.483 10−6 mol/L | 0.483 10−6 mol/L | | WRL-68 | Normal hepatic cells | 0.773 10−6 mol/L | 0.773 10−6 mol/L | 0.773 10−6 mol/L |
| | (2) | MCF-7 | Breast cancer cells | 7.609 10−6 mol/L | 6.621 10−6 mol/L | 5.910 10−6 mol/L | | MCF-10 | Normal breast cells | 0.483 10−6 mol/L | 0.483 10−6 mol/L | 0.483 10−6 mol/L | | WRL-68 | Normal hepatic cells |
0.773 10−6 mol/L | 0.773 10−6 mol/L | 0.773 10−6 mol/L |
| | Doxorubicin | MCF-7 | Breast cancer cells | 4.471 10−6 mol/L | 4.195 10−6 mol/L | 3.827 10−6 mol/L |
|
|
